Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Getafe – page 218

3 196 clinical trials in Getafe, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Getafe at a glance
3 196
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 196 trials in Getafe

Open in trial search

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors - First human trial to evaluate safety and effectiveness

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Alopecia areata

Not recruiting

Long-Term Study of Ritlecitinib Tosilate for Adults and Adolescents with Alopecia Areata

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic lymphocytic leukaemia

Not recruiting

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Transitional cell carcinoma

Not recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide and Formoterol Fumarate for Patients with Poorly Controlled Asthma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Transplant rejection

Not recruiting

Study on Riliprubart for Preventing and Treating Antibody-Mediated Rejection in Adult Kidney Transplant Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary hypertension

Not recruiting

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Non-small cell lung cancer

Not recruiting

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Biogen Idec Research Limited

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Getafe

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Groundbreaking research focusing on pneumococcal disease prevention and treatment of acute respiratory distress syndrome, including innovative vaccine development and therapeutic approaches.

  • Pneumococcal Vaccines
  • ARDS Treatment
  • Community-Acquired Pneumonia

Studies aim to enhance protection against respiratory infections and improve patient outcomes in severe cases.

02 Neurological Disorders

Innovative clinical trials exploring treatments for multiple sclerosis and Menière's disease, focusing on disease modification and symptom management.

  • MS Treatment Comparisons
  • Inner Ear Disorders
  • Neurological Therapeutics

Research aims to improve quality of life and disease management for patients with chronic neurological conditions.

03 Cardiovascular & Renal Studies

Comprehensive research into chronic renal disease, pulmonary embolism, and vascular conditions, evaluating new therapeutic approaches.

  • Renal Disease Management
  • Pulmonary Embolism Treatment
  • Vascular Health

Studies focus on improving outcomes in patients with complex cardiovascular and kidney conditions.

04 Oncology & Specialized Care

Advanced research in prostate cancer treatment and management of vitiligo, exploring innovative therapeutic options.

  • Cancer Treatment
  • Dermatological Conditions
  • Specialized Therapies

Trials aim to develop more effective treatments for both oncological and dermatological conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.